Please use this identifier to cite or link to this item:
http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/9421
Title: | A randomized phase II/III trial of rosuvastatin with neoadjuvant chemo-radiation in patients with locally advanced rectal cancer |
Authors: | GUPTA, EKTA GALANDE, SANJEEV et. al. Dept. of Biology |
Keywords: | rosuvastatin Pathological complete response Neoadjuvant chemoradiation Rectal cancer drug repurposing 2025-MAR-WEEK4 TOC-MAR-2025 2025 |
Issue Date: | Mar-2025 |
Publisher: | Frontiers |
Citation: | Frontiers in Oncology, 15. |
Abstract: | Statins have been shown to improve the possibility of a pathological complete response (pCR) in patients with locally advanced rectal cancer when given in combination with neo-adjuvant chemo-radiation (NACTRT) in observational studies. The primary objective of this phase II randomized controlled trial (RCT) is to determine the impact of rosuvastatin in improving pCR rates in patients with locally advanced rectal cancer who are undergoing NACTRT. The secondary objectives are to compare adverse events, postoperative morbidity and mortality, disease-free survival (DFS), and overall survival in the two arms and to identify potential prognostic and predictive factors determining outcomes. If the study is positive, we plan to proceed to a phase III RCT with 3-year DFS as the primary endpoint. |
URI: | https://doi.org/10.3389/fonc.2025.1450602 http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/9421 |
Appears in Collections: | JOURNAL ARTICLES |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.